Sutro Biopharma, Inc. (STRO)
| Market Cap | 675.16M +789.2% |
| Revenue (ttm) | 102.48M +65.2% |
| Net Income | -191.09M |
| EPS | -22.49 |
| Shares Out | 16.57M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 69,614 |
| Open | 39.91 |
| Previous Close | 39.83 |
| Day's Range | 39.81 - 41.88 |
| 52-Week Range | 6.74 - 41.88 |
| Beta | 1.64 |
| Analysts | Buy |
| Price Target | 31.33 (-23.12%) |
| Earnings Date | May 19, 2026 |
About STRO
Sutro Biopharma, Inc. operates as an oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF; and site-specific conjugation platform, XpressCF+. Its lead product candidate includes STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including non-small cell lung cancer, head and neck squamous cell carcinoma, cervical cancer, colorectal cancer, pancreatic ductal adenocarcin... [Read more]
Financial Performance
In 2025, Sutro Biopharma's revenue was $102.48 million, an increase of 65.18% compared to the previous year's $62.04 million. Losses were -$191.09 million, -15.99% less than in 2024.
Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for STRO stock is "Buy." The 12-month stock price target is $31.33, which is a decrease of -23.12% from the latest price.
News
Sutro Biopharma initiated with an Outperform at Mizuho
Mizuho initiated coverage of Sutro Biopharma (STRO) with an Outperform rating and $50 price target The firm believes the company’s antibody-drug conjugate pipeline is positioned to reproduce a proven ...
Sutro Biopharma price target raised to $41 from $35 at Citizens
Citizens raised the firm’s price target on Sutro Biopharma (STRO) to $41 from $35 and keeps an Outperform rating on the shares. Recent AACR presentations highlighted strong preclinical results across
Sutro Biopharma presents preclinical data across its pipeline of ADCs
Sutro Biopharma (STRO) announced promising preclinical data across its pipeline of next- generation ADCs in five posters and one oral presentation at the American Association for Cancer Research, AACR...
Sutro Biopharma price target raised to $35 from $23 at Citizens
Citizens analyst Reni Benjamin raised the firm’s price target on Sutro Biopharma (STRO) to $35 from $23 and keeps an Outperform rating on the shares. The firm continues to believe
Sutro Biopharma management to meet with Citizens
Meeting to be held in San Diego on April 20 hosted by Citizens.
Sutro Biopharma initiated with an Outperform at Leerink
Leerink initiated coverage of Sutro Biopharma (STRO) with an Outperform rating and $38 price target The company is focusing on novel approaches to optimize antibody drug conjugates to enhance the
Sutro Biopharma price target raised to $55 from $51 at Deutsche Bank
Deutsche Bank raised the firm’s price target on Sutro Biopharma (STRO) to $55 from $51 and keeps a Buy rating on the shares. The firm says the company’s Q4 report
Sutro Biopharma upgraded to Buy from Neutral at H.C. Wainwright
H.C. Wainwright upgraded Sutro Biopharma (STRO) to Buy from Neutral with a price target of $28, up from $10. The firm has increased conviction that STRO-004 “will deliver on promises
Wells upgrades Sutro to Overweight ahead of STRO-004 data
Wells Fargo analyst Derek Archila upgraded Sutro Biopharma (STRO) to Overweight from Equal Weight with a price target of $27, up from $8, post the Q4 report. The update was
Sutro Biopharma upgraded to Overweight from Equal Weight at Wells Fargo
Wells Fargo upgraded Sutro Biopharma (STRO) to Overweight from Equal Weight with a price target of $27, up from $8.
Sutro Biopharma files $300M mixed securities shelf
17:24 EDT Sutro Biopharma (STRO) files $300M mixed securities shelf
Sutro Biopharma Reports Full Year 2025 Financial Results and Business Highlights
– Dosed three cohorts in Phase 1 trial of STRO-004, potential best-in-class Tissue Factor (TF) ADC; on track to report initial clinical data in mid-2026 –
Sutro Biopharma Transcript: The Citizens Life Sciences Conference 2026
A major strategic pivot has accelerated a differentiated ADC pipeline, with STRO-004 in phase I and two more programs set for INDs this year. The cell-free platform enables higher drug exposure and safety, while dual payload ADCs aim to overcome resistance. Key data and milestones are expected within the next 12 months.
Sutro Biopharma Transcript: TD Cowen 46th Annual Health Care Conference
A new leadership team has transformed operations, extended financial runway, and accelerated clinical programs, notably advancing a differentiated ADC pipeline. The lead program, STRO-004, is in clinical trials with top-line data expected mid-year, aiming for broad tumor impact and improved safety.
Sutro Biopharma to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format ...
Sutro Biopharma 7.87M share Secondary priced at $13.98
Leerink, TD Cowen and LifeSci Capital are acting as joint book running managers for the offering.
Sutro Biopharma Announces Pricing of $110.0 million Underwritten Offering
SOUTH SAN FRANCISCO, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (Nasdaq: STRO), a clinical-stage oncology company pioneering site-specific and novel-format ...
Sutro Biopharma upgraded to Outperform from Market Perform at Citizens
Citizens upgraded Sutro Biopharma (STRO) to Outperform from Market Perform with a $23 price target The firm cites its platform and cash per share value analysis for the upgrade following
Sutro Biopharma Transcript: 44th Annual J.P. Morgan Healthcare Conference
A strategic pivot and new leadership have transformed the company, streamlining operations and accelerating a differentiated ADC pipeline. Key programs, including single and dual payload ADCs, are advancing rapidly, with robust preclinical and early clinical data, extended cash runway, and strategic partnerships supporting future growth.
Sutro Biopharma regains compliance with Nasdaq
Sutro Biopharma (STRO) announced it has regained compliance with Nasdaq continued listing standard for minimum share price under Rule 5450 of the Nasdaq Listing Qualifications.
Sutro Biopharma price target raised to $51 from $5 at Deutsche Bank
Deutsche Bank raised the firm’s price target on Sutro Biopharma (STRO) to $51 from $5 and keeps a Buy rating on the shares. The company’s STRO-004 is entering the Clinic
Sutro Biopharma Transcript: Piper Sandler 37th Annual Healthcare Conference
Significant progress was highlighted in ADC platform innovation, with rapid clinical advancement of STRO-004 and plans for multiple new INDs. Dual payload and immunostimulatory ADCs are key pipeline differentiators, supported by a strong financial runway into 2027.
Sutro Biopharma Transcript: R&D Day 2025
A diversified ADC pipeline is advancing with STRO-004 in the clinic, STRO-006 and PTK7 dual payload ADCs targeting INDs in 2026-2027, and strong preclinical data supporting broad tumor applications. Platform innovations and partnerships have extended the financial runway and positioned the company for multiple clinical milestones in 2026.
Sutro Biopharma Reports Third Quarter 2025 Financial Results and Business Highlights
– Company announces U.S. FDA clearance of Investigational New Drug (IND) application for STRO-004, its potential best-in-class Tissue Factor ADC; Expects to dose first patient before year-end –
Sutro Biopharma to Host Virtual Research & Development Day on November 12, 2025
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug ...